BiotechTube
PharmaDiall

PharmaDiall

Brussels, Europe - Other· Est.
pharmadiall.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

PharmaDiall is a private, clinical-stage biotech developing original small molecule therapeutics, with a lead program in anticoagulation. The company's flagship drug, Dimolegin, has completed Phase 3 trials in Russia, demonstrating efficacy in COVID-19-associated thrombosis and showing promise in post-surgical settings. While its initial regulatory and commercial focus appears centered on the Russian market, the company is based in Brussels and targets the multi-billion dollar global anticoagulant market with a potential best-in-class candidate.

CardiovascularThrombosis

Technology Platform

Integrated small molecule drug discovery and development platform encompassing medicinal chemistry, preclinical testing, and clinical trial execution.

Opportunities

Dimolegin has received marketing authorization in Russia, providing a near-term revenue opportunity in a multi-billion ruble market.
Its once-daily dosing and claimed superior PK profile present a potential differentiation in the global DOAC market.
The drug's clinical data in niche indications like COVID-19-associated coagulopathy may offer initial market entry points.

Risk Factors

The company is heavily dependent on the success of its single asset, Dimolegin, and on the Russian market, exposing it to significant pipeline and geopolitical concentration risk.
It faces extreme competition from entrenched, blockbuster DOACs with vast clinical and commercial resources.
The private company's financial runway and ability to fund broader development are unclear.

Competitive Landscape

PharmaDiall competes in the massive Direct Oral Anticoagulant (DOAC) market dominated by global giants like Bayer/J&J (Xarelto), BMS/Pfizer (Eliquis), and Boehringer Ingelheim (Pradaxa). Its strategy is to differentiate Dimolegin through potentially superior pharmacokinetics and once-daily dosing, aiming to capture market share in Russia before potentially challenging incumbents in broader indications.

More companies in Small Molecule Drugs →More companies in Europe - Other →